Pluristem Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Pluristem Therapeutics generated cash of -$30,910,000, which is less than the previous year. Cash used in financing activities reached the amount of $61,402,000 last year. Net change in cash is therefore $22,609,000.
Cash Flow
| 2012 | -3.27M | -30.79M | 632K |
|---|---|---|---|
| 2013 | -16.88M | -19.79M | 36.30M |
| 2014 | -19.12M | 1.98M | 12.62M |
| 2015 | -20.60M | 21.53M | 17.20M |
| 2016 | -18.52M | 1.31M | 807K |
| 2017 | -21.61M | 4.29M | 15.79M |
| 2018 | -21.38M | 5.57M | 19.92M |
| 2019 | -29.45M | 1.17M | 23.58M |
| 2020 | -26.36M | -30.45M | 60.87M |
| 2021 | -30.91M | -7.26M | 61.40M |
PSTI Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 9.22M | 5.18M | 9.88M | 4.70M | 6.22M | 22.62M | 4.49M | 9.00M | 9.38M | 42.82M |
Operating activities | ||||||||||
Net income | -49.86M | -29.15M | -35.30M | -26.12M | -27.81M | -23.24M | -24.67M | -26.93M | -21.15M | -14.79M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.37M | 1.57M | 1.96M | 2.01M | 2.17M | 2.15M | 2.07M | 1.90M | 1.03M | 435K |
Stock-based compensation expense | 13.96M | 2.56M | 5.14M | 6.54M | 3.66M | 3.07M | 4.05M | 5.85M | 2.79M | 4.92M |
| Deferred income tax benefit | 13.96M | 2.56M | 5.14M | 6.54M | 3.66M | 3.07M | 4.05M | 5.85M | 2.79M | 4.92M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 37K | -121K | 978K | 1.19M | -537K | 572K | -1.99M | 0 | -166K |
Inventories | 0 | -789K | -18.48M | -21.93M | -24.22M | 2.63M | -2.10M | 664K | 0 | 0 |
Accounts payable | 578K | -291K | -863K | 1.21M | -701K | -77K | -566K | 1.25M | 1.33M | -424K |
Cash generated by operating activities | -30.91M | -26.36M | -29.45M | -21.38M | -21.61M | -18.52M | -20.60M | -19.12M | -16.88M | -3.27M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -30.18M | 0 | -15.97M | -3.60M | -5.06M | -4.90M | -10.85M | -18.73M | -8.16M |
Investments In Property Plant And Equipment | -373K | -270K | -239K | -342K | -378K | -1.75M | -831K | -1.57M | -4.30M | -1.48M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -7.26M | -30.45M | 1.17M | 5.57M | 4.29M | 1.31M | 21.53M | 1.98M | -19.79M | -30.79M |
Financing activities | ||||||||||
Common Stock Issued | 36.58M | 58.16M | 23.46M | 18.63M | 15.71M | 790K | 16.91M | 10.64M | 34.10M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 61.40M | 60.87M | 23.58M | 19.92M | 15.79M | 807K | 17.20M | 12.62M | 36.30M | 632K |
Net Change In Cash | 22.60M | 4.04M | -4.70M | 4.11M | -1.51M | -16.40M | 18.13M | -4.51M | -382K | -33.44M |
Cash at end of period | 31.83M | 9.22M | 5.18M | 8.82M | 4.70M | 6.22M | 22.62M | 4.49M | 9.00M | 9.38M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |